

Orthocell Achieves a Record \$2.73m in Revenue for June Quarter Strong Remplir™ Sales Achieved in Australia

- Record revenue of \$2.73 million for the June quarter, underscoring Orthocell's market penetration and sales growth of its flagship nerve repair product Remplir™ in Australia.
- Revenue for the June quarter up 22.8% on the previous quarterly record of \$2.22 million achieved in the March quarter.
- The result is the fifth consecutive quarter of record revenue for the Company increasing Orthocell's quarterly revenue growth trajectory of a Compound Quarterly Growth Rate ("CQGR") of 9.5% over the last 3 years.
- Importantly, this outstanding result does not yet include revenue from Remplir™ sales in the US, which are expected to ramp up during the first half of FY26.
- US Remplir commercialisation program remains on track following recent first surgical use of Remplir™ in the US, a crucial step in building surgical experience and knowledge in the early phase of the US rollout.
- Orthocell's 14 specialist nerve distributors for Remplir™ in the US expected to expand customer networks across 25 US states and accelerate revenue growth in the US\$1.6 billion¹ US market.
- Orthocell has a strong balance sheet with approximately ~A\$28.5 million cash at bank with no debt, and is very well funded to continue to broaden its commercial footprint and grow revenues in existing and new markets.
- Chairman and CEO to conduct webinar Wednesday 2 July at 10amWST/12pmEST. Details below.

Perth, Australia; 1 July 2025: Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce the achievement of a record \$2.73 million in revenue for the quarter ended 30 June 2025, up 22.8% on the previous record of \$2.22m in the March 25 quarter. Notably, this revenue result was achieved prior to any contribution from Remplir™ sales in the US, which are expected to ramp up during the first half of FY26, and underscores the Company's commercial momentum and growing penetration in existing markets of its flagship nerve repair product Remplir™.


The material revenue uplift in the quarter was largely driven by stronger demand for Remplir in Australia, reflecting continued traction with surgeons due to the superior, consistent and predictable outcomes surgeons can achieve using Orthocell's products. This is evidenced by Remplir now being used by >200 surgeons across >165 hospitals and which continues to consistently grow. The result continues Orthocell's quarterly revenue growth trajectory of a Compound Quarterly Growth Rate ("CQGR") of 9.5% over the last 3 years.

¹ USA nerve repair market size was estimated using referenced papers from both US and OUS databases and studies.



Orthocell's quarterly revenue performance since the commencement of FY23 is as follows:

Figure 1 – Quarterly Revenue



Quarterly revenue has grown by 9.5% compounded for the last ten quarters following the product launches in Q2 FY23.

Revenue is up 22.8% from \$2.22 million in March 25 Quarter to \$2.73 million in June 25 Quarter.

*CQGR = Compound Quarterly Growth Rate

As mentioned, this revenue result was achieved prior to any contribution from Remplir™ sales in the US, which are expected to ramp up during the first half of FY26. The Company anticipates that US sales will gather pace in the coming months as more surgeons and healthcare professionals gain familiarity with Remplir™. Orthocell recently announced the successful completion its first surgery using Remplir™ in the US, a significant milestone in the Company's US market rollout. Orthocell's US network of 14 specialist nerve distributors with mature, direct-to-surgeon, hospital and other customer relationships across 25 US states will support the expected ramp up of sales in this market.

Orthocell CEO and MD, Paul Anderson, said: "Achieving a record of \$2.73 million in revenue for the June quarter reflects the continued strong market response to our market leading products Striate and Remplir. This outstanding result is driven by growing demand from surgeons in our existing markets and lays a solid foundation for our US expansion which we expect to ramp up in the first half of FY26.

We're seeing our commercialisation strategy in Australia starting to bear fruit and we are confident this will be replicated on a much larger scale in the US.

With our highly experienced US distributors appointed and our first surgical use completed after achieving FDA clearance, we are well-positioned to accelerate growth in the US\$1.6 billion nerve repair market over the coming months."

Remplir is a collagen wrap used in nerve repair surgery to assist surgeons to improve outcomes in the repair and regeneration of damaged nerves. It is supported by robust clinical evidence, including recent studies

confirming its superiority over standard suture techniques in nerve regeneration, earlier return to function, and higher quality nerve tissue restoration.

Orthocell is targeting a large global addressable nerve repair market estimated to be worth in excess of US\$3.5 billion² with an estimated ~2.0M peripheral nerve repairs performed across Australia/New Zealand, Singapore, USA, EU/UK, Canada, Brazil, Japan, Hong Kong and Thailand.

The Company has a strong balance sheet with approximately ~A\$28.5million cash at bank and no debt and is very well funded to continue to broaden its commercial footprint and grow revenues in existing and new markets.

Company Webinar

Orthocell's Chairman, Mr John Van Der Wielen and CEO and Managing Director Mr Paul Anderson will conduct a webinar on Wednesday 2 July at 10amWST/12pmEST to provide an overview of its first US surgical use of Remplir and an update on the progress of the US roll out of Remplir.

Details of the webinar are as follows:

Investor Briefing – Webinar

- [When: 10:00am WST | 12:00pm EST Wednesday 2 July 2025](#)
- [Register Now: CLICK HERE](#)

[After registering, you will receive a confirmation email containing information about joining the webinar.](#)

Release authorised by:

Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited
CEO and MD

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Haley Chartres
HACK Director

P: +61 423 139 163

E: haley@hck.digital

Investor enquiries

Shaun Duffy
VECTOR Advisors

P: +61 404 094 384

E: sduffy@vectoradvisors.au

² Company estimate of addressable market size for Remplir (AUS, NZ, SGP, USA, EU/UK, CAN, BRZ, JAP & THA). Sources include iData Research Inc and other publicly available market research reports and published literature.



About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed 14 US distributors, with first sales expected to follow shortly. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore and is distributed exclusively by Device Technologies Group. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

